Clinical Trials Directory

Trials / Completed

CompletedNCT04736979

Antibiotic PRophylAxis Based on infeCTIve Risk in Cardiac Implantable Electronic Device

Antibiotic PRophylAxis Based on infeCTIve Risk in Cardiac Implantable Electronic Device - PRACTICE Study

Status
Completed
Phase
Study type
Observational
Enrollment
1,044 (actual)
Sponsor
University Hospital of Ferrara · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study was aimed at the evaluation of a new protocol of antibiotic prophylaxis, stratified according to individual infective risk calculated with the Shariff score at the moment of cardiac implantable electronic device (CIED) implantation.

Detailed description

Prospective, single centre, cohort study. Patients undergoing CIED surgery in a 3-years period were considered for participation. In particular, patients were eligible if undergoing first implantation or replacement or upgrade of pacemaker or implantable cardioverter-defibrillator (ICD), including cardiac resynchronization therapy (CRT). At the time of enrolment, before index procedure, the Shariff score was calculated for every patient. According to the score, patients were stratified in two groups: low infective risk (score \<3) and high infective risk (score ≥3). Two different protocols of antibiotic prophylaxis were administered according to risk stratification. Patients in the "low risk" group were treated with only two doses of antibiotics, both intravenous, of whom the first one hour before skin incision and the second after eight hours. Patients in the "high risk" group were treated with intravenous prophylaxis for two full days (of whom the first administration one hour before skin incision and the others every eight hours), followed by other seven days of oral prophylaxis, for a total of nine days. Thereby, every patient received one administration of intravenous antibiotic one hour before skin incision and a second administration after eight hours, while patients in the low risk group did not receive other antibiotics and patients in the high risk group continued intravenous antibiotics every eight hours for two days, followed by oral antibiotics for other seven days. The intended drug for antibiotic prophylaxis was amoxicillin + clavulanic acid unless the patient had a history of allergic reactions to penicillin. The dosage was dependent on renal function: for intravenous amoxicillin + clavulanic acid 2.2 g in patients with creatinine clearance (CrCl) \<30 ml/min and 1.2 g in patients with CrCl \>30ml/min, for oral amoxicillin + clavulanic acid 1 g every 8 hours in patients with \<30 ml/min and 1 g every 12 hours in patients with CrCl \>30ml/min. In case of penicillin allergy, clindamycin was chosen. The intravenous dosage was 600 mg every 8 hours for CrCl \<30 ml/min and 600 mg every 12 hours for CrCl \>30 ml/min, while the oral dosage was 450 mg every 8 hours for CrCl \<30 ml/min and 450 mg every 12 hours for CrCl \>30 ml/min. Patients who were already in antibiotic therapy at the time of index procedure (for reasons other than CIED implantation) were not stratified in one of the two groups: post-operative antibiotics were continued according to clinical indications and not to the study protocol. This group included patients with a documented or suspected infection before surgery in whom the CIED procedure was judged not deferrable.

Conditions

Interventions

TypeNameDescription
DRUGamoxicillin clavulanatedosage according to Shariff score and creatinine clearance

Timeline

Start date
2017-01-01
Primary completion
2020-08-31
Completion
2020-08-31
First posted
2021-02-03
Last updated
2022-04-29

Source: ClinicalTrials.gov record NCT04736979. Inclusion in this directory is not an endorsement.